At bioXcellerator, 316 patients with degenerative disc disease have been treated with MSC therapy from September 2020 to September 2022.
The population treated is predominantly male (see figure 2), ranging from 21 to 85 years in age. Half of the patients were less than 47 years of age.
Patients from more than 24 countries have visited us for treatment for DDD, mostly from the United States (82%) and Canada (5.1%) as shown and to a lesser extent by other countries represented in Figure 3.
Affected vertebral level
The following is the distribution of affected discs per spinal segment.
Visual Analog Pain Scale - VAS: used to measure pain intensity, ranging from 0 (no pain) to 10
Oswestry Disability Index – ODI: used to quantify disability related to low back pain and consists of 10 questions. The final score ranges from 0 to 100, with the following interpretation: 0% to 20% - minimal disability, 21%-40% - moderate disability, 41%-60% - severe disability, 61%-80% - disabled, 81%-100% - prostration. The percentage changes are calculated based on the total available scores. So, a change from 20 to 10, with a total range of 0 to 100, would represent a 10% decrease.
Neck Disability Index - NDI: the NDI includes 10 questions and is used to determine how neck pain affects a patient's daily life and to assess the self-reported disability of patients with neck pain. The final score ranges from 0 (no disability) to 100 (total disability). The percentage changes are calculated based on the total available scores. So, a change from 20 to 10, with a total range of 0 to 100, would represent a 10% decrease.
A sample of 30 (10% of patients treated) had completed follow-up for up to 6 months using all 3 assessment scales. Figure 6 shows the progression of pain using the VAS. Figure 7 shows the improvement of physical limitation measured with the NDI for patients with cervical DDD. Figure 8 shows the improvement of physical limitation, measured with the ODI scale for patients with DDD of the non-cervical segments.
Our review of patients treated at bioXcellerator between September 2020 and September 2022 demonstrates an improvement in pain and functional limitation of patients with DDD at all segments of the spine when evaluated with clinical scales at 3 and 6 months in comparison to the pre-therapy baseline evaluation.
This report was prepared by Scientific Direction Board from internal data sources on November 01, 2022.